Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | ENPEP | Q07075 | 13/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3396691 | 1.00 | ALDH1A1 (0.46) | ALDH1A1ENPEPMEN1LMNAKMT2A | |
| SCHEMBL32677554 | 0.92 | ENPEP (0.40) | ALDH1A1ENPEPMEN1LMNAKMT2A | |
| SCHEMBL20769311 | 0.92 | ENPEP (0.44) | ALDH1A1ENPEP | |
| SCHEMBL20769310 | 0.92 | ENPEP (0.44) | ALDH1A1ENPEP | |
| SCHEMBL29582522 | 0.89 | CTSD (0.45) | ENPEPCTSD | |
| SCHEMBL27772445 | 0.88 | ALDH1A1 (0.49) | ALDH1A1ENPEPMEN1LMNAKMT2A | |
| SCHEMBL27772443 | 0.88 | ALDH1A1 (0.49) | ALDH1A1ENPEPMEN1LMNAKMT2A | |
| SCHEMBL30051624 | 0.87 | ALDH1A1 (0.50) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL31151823 | 0.87 | GRIN2D (0.51) | ENPEPCTSD | |
| SCHEMBL15692392 | 0.86 | ALDH1A1 (0.46) | ALDH1A1ENPEPMEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20250152692-A1 | IMMUNOGENS TARGETING ANTHRAX | UNIV MICHIGAN REGENTS (US) | 2025-05-15 | — | — | US | disclosed |
| EP-4440605-A1 | IMMUNOGENS TARGETING ANTHRAX | The Regents of The University of Michigan (US) | 2024-10-09 | — | — | EP | disclosed |
| WO-2023102483-A1 | IMMUNOGENS TARGETING ANTHRAX | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20220411475-A1 | HYBRID VIRUS-LIKE PARTICLES AND USE THEREOF AS A THERAPEUTIC HEPATITIS B VACCINE | VLP BIOTECH, INC. (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| US-11235045-B2 | Hybrid hepadnavirus cores carrying multiple malaria parasite epitopes | VLP BIOTECH, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| EP-2248821-B1 | SUBSTRATE FOR ASSAYING -GLUCAN AND/OR ENDOTOXIN AND ASSAY METHOD | WAKO PURE CHEM IND LTD (JP) | 2015-01-28 | — | — | EP | disclosed |
| EP-2248821-A1 | SUBSTRATE FOR ASSAYING -GLUCAN AND/OR ENDOTOXIN AND ASSAY METHOD | Wako Pure Chemical Industries, Ltd. (JP) | 2010-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | ALDH1A1 3596/4885ENPEP 18/4885MEN1 1217/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | ALDH1A1 4110/4885ENPEP 5/4885MEN1 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.